These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25785014)

  • 1. Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
    Kong P; Zhang B; Lei P; Kong X; Zhang S; Li D; Zhang Y
    Int J Clin Exp Med; 2015; 8(1):431-9. PubMed ID: 25785014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R; Ebadi M; Pfeiffer RF
    Neurosci Lett; 1995 Nov; 200(2):77-80. PubMed ID: 8614567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP
    Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J
    J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?
    Damier P; Kastner A; Agid Y; Hirsch EC
    Neurology; 1996 May; 46(5):1262-9. PubMed ID: 8628464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels.
    Themann C; Alvarez Fischer D; Gross S; Westermann R; Weihe E; Kuschinsky K; Schäfer H; Ferger B
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):22-8. PubMed ID: 11862330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
    Seif-El-Nasr M; Atia AS; Abdelsalam RM
    Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
    J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
    Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
    Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM
    Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS; Schneider JS
    Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
    Wang X; Yang HA; Wang XN; Du YF
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.
    Thiffault C; Lamarre-Théroux L; Quirion R; Poirier J
    Brain Res Mol Brain Res; 1997 Mar; 44(2):238-44. PubMed ID: 9073165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway.
    Vrana SL; Azzaro AJ; Vrana KE
    Mol Pharmacol; 1992 May; 41(5):839-44. PubMed ID: 1350320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.